In this 15-minute lecture from Rebellion in EM 2021, George Willis, MD discusses acute ischemic stroke and the evidence base for and against thrombolysis.
George Willis, MD
University of Texas Health Science Center in San Antonio
The use of thrombolytics in stroke has been a controversial one for many years. There is a constant questioning of risk vs. benefit that anyone tasked with this decision has to deal with. Two papers have shown a benefit for patients within a 3 hour window and even one with an extended 4.5 hour window since symptom onset that people have lauded since their publication. However, there have been some recent publications calling into question the validity of these 2 studies.
- Discuss the re-analysis of the NINDS-II and ECASS-3 trial and their clinical implications
Post Peer Reviewed By: Salim R. Rezaie, MD (Twitter: @srrezaie)
Latest posts by Salim Rezaie (see all)
- The CLASSIC Trial: IV Fluid Restriction in Septic Shock - June 23, 2022
- REBEL Cast Ep110: The COVI-PRONE Trial – Awake Prone Positioning and COVID-19 - June 20, 2022
- Tenecteplase vs Alteplase in Acute Ischemic Stroke - June 16, 2022